What is a 503B outsourcing facility, and how is it different from a 503A pharmacy?
A 503B outsourcing facility is an FDA-registered compounder that can make drugs in bulk, without a prescription for each patient, and is inspected under federal manufacturing rules. FDA proposed on April 30, 2026 not to let 503B facilities compound semaglutide, tirzepatide or liraglutide from bulk; no final decision was found as of November 20, 2026.
Released · Last reviewed · how we verify
Limitations of this answer
Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy. This page reports prices and terms; whether any GLP-1 suits you is a decision for you and a licensed clinician.
Frequently asked
What is a 503B outsourcing facility, and how is it different from a 503A pharmacy?
A 503B outsourcing facility is an FDA-registered compounder that can make drugs in bulk, without a prescription for each patient, and is inspected under federal manufacturing rules. FDA proposed on April 30, 2026 not to let 503B facilities compound semaglutide, tirzepatide or liraglutide from bulk; no final decision was found as of November 20, 2026.
How current are the prices on TopGLP1Providers?
Every price on TopGLP1Providers carries the date it was read on the program’s own page; the whole dataset was re-read on November 20, 2026, from 2026-11-21 00:33 to 00:57 UTC, and NexLife’s plan pages were checked again for this site on November 21 (UTC). Programs whose pages refused automated reads that day, such as TrimRx, MEDVi, bmiMD, Embody, Ro and Hims & Hers, show no current price rather than an older one. When a program changes its price, the record, the pages that cite it and the changelog are updated together.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)